Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Show more

2265 Upper Middle Road East, Oakville, ON, L6H 0G5, Canada

Drug Manufacturers - Specialty & Generic
Healthcare
Start AI Chat

Market Cap

110.1M

52 Wk Range

$0.77 - $1.59

Previous Close

$0.99

Open

$1.00

Volume

274,894

Day Range

$0.99 - $1.03

Enterprise Value

74.14M

Cash

11.62M

Avg Qtr Burn

-6.925M

Insider Ownership

3.14%

Institutional Own.

20.04%

Qtr Updated

09/30/25